Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 101: Dietary fats are transported from the gastrointestinal tract to adipocytes in what form?

A. Diacylglycerol
B. Triacylglycerol
C. Fat micelles
D. Chylomicrons (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Chylomicrons** The transport of dietary (exogenous) lipids is a multi-step process. After ingestion, dietary triacylglycerols (TAGs) are broken down into free fatty acids and 2-monoacylglycerols in the intestinal lumen. These are absorbed by the enterocytes, where they are **re-esterified back into TAGs**. Because TAGs are hydrophobic, they cannot travel freely in the blood. They are packaged into **Chylomicrons**—large lipoprotein particles containing a core of TAGs and cholesteryl esters, surrounded by phospholipids and **Apolipoprotein B-48**. These chylomicrons enter the lymphatic system (lacteals) and eventually the bloodstream to deliver fats to adipocytes and muscle. **Why the other options are incorrect:** * **A & B (Diacylglycerol/Triacylglycerol):** While TAGs are the primary lipid being transported, they are insoluble in plasma. They must be packaged into a lipoprotein (Chylomicron) to be transported from the gut to peripheral tissues. * **C (Fat micelles):** Micelles are temporary aggregates of mixed lipids and bile salts formed within the **intestinal lumen** to facilitate absorption into the enterocyte. They do not enter the circulation. **High-Yield NEET-PG Pearls:** * **Apo B-48** is the characteristic structural marker for chylomicrons (formed via RNA editing of the Apo B gene). * **Lipoprotein Lipase (LPL)**, activated by **Apo C-II**, is the enzyme on capillary walls that hydrolyzes chylomicron TAGs for uptake by adipocytes. * **Milky serum** after a fatty meal is due to the presence of chylomicrons. * **Abetalipoproteinemia** is a clinical condition where a deficiency in Microsomal Triglyceride Transfer Protein (MTP) prevents chylomicron formation, leading to fat malabsorption and steatorrhea.

Question 102: Which of the following sources of cholesterol is most important for sustaining adrenal steroidogenesis when it occurs at a high rate for a long time?

A. De novo synthesis of cholesterol from acetate
B. Cholesterol in LDL particles (Correct Answer)
C. Cholesterol in the plasma membrane
D. Cholesterol in lipid droplets within adrenal cortical cells

Explanation: **Explanation:** The adrenal cortex requires a continuous supply of cholesterol as the precursor for steroid hormones (cortisol, aldosterone, and androgens). While the adrenal gland can obtain cholesterol from multiple sources, the **uptake of plasma LDL (Low-Density Lipoprotein)** via receptor-mediated endocytosis is the most critical source during periods of sustained, high-rate steroidogenesis. * **Why Option B is Correct:** Under basal conditions, the adrenal gland utilizes stored cholesterol. However, when stimulated by ACTH for prolonged periods, the intracellular stores are rapidly depleted. To sustain high output, the gland upregulates LDL receptors to extract cholesterol from the circulation. This exogenous source provides the bulk of the cholesterol needed for chronic steroid production. * **Why Option A is Incorrect:** While the adrenal gland can synthesize cholesterol *de novo* from acetate (HMG-CoA reductase pathway), this process is energetically expensive and too slow to meet the demands of maximal, long-term steroidogenesis. * **Why Option C is Incorrect:** The plasma membrane contains cholesterol, but it is structural. Utilizing it would compromise the integrity of the cell membrane; it is not a primary metabolic reservoir. * **Why Option D is Incorrect:** Lipid droplets (cholesteryl esters) are the primary source for **acute, immediate** responses. However, they are finite. For **long-term** (chronic) demand, these stores are insufficient and must be replenished by LDL. **High-Yield NEET-PG Pearls:** * **Rate-limiting step of Steroidogenesis:** The conversion of cholesterol to pregnenolone by the enzyme **Desmolase** (CYP11A1/P450scc) in the mitochondria. * **StAR Protein:** The Steroidogenic Acute Regulatory (StAR) protein is essential for transporting cholesterol into the inner mitochondrial membrane. * **Wolman Disease:** A rare lysosomal storage disease where a deficiency in acid lipase prevents the release of free cholesterol from LDL, leading to adrenal insufficiency.

Question 103: Which of the following is a primary ketone body?

A. Acetoacetate (Correct Answer)
B. Acetone
C. Beta-hydroxybutyrate
D. All are primary ketone bodies

Explanation: **Explanation:** Ketone bodies are produced in the liver mitochondria during states of high fatty acid oxidation (e.g., starvation, uncontrolled diabetes). The process, known as ketogenesis, follows a specific enzymatic sequence that determines which ketone body is "primary." **1. Why Acetoacetate is the Correct Answer:** Acetoacetate is termed the **primary ketone body** because it is the first ketone body synthesized in the liver. The pathway involves the condensation of Acetyl-CoA molecules to form HMG-CoA, which is then cleaved by **HMG-CoA lyase** to produce Acetoacetate. All other ketone bodies are derived from this parent molecule. **2. Analysis of Incorrect Options:** * **B. Acetone:** This is a secondary ketone body formed by the **spontaneous (non-enzymatic) decarboxylation** of acetoacetate. It is metabolic waste, cannot be utilized for energy, and is excreted via the lungs (causing "fruity breath"). * **C. Beta-hydroxybutyrate:** This is also a secondary ketone body formed by the **enzymatic reduction** of acetoacetate by the enzyme *β-hydroxybutyrate dehydrogenase*. While it is the most abundant ketone body in the blood during ketosis, it is chemically a derivative of acetoacetate. * **D. All are primary:** Incorrect, as only acetoacetate is the initial product of the ketogenic pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Ketogenesis:** Liver mitochondria (but the liver **cannot** utilize ketones because it lacks the enzyme **Thiophorase/β-ketoacyl-CoA transferase**). * **Rate-limiting enzyme:** HMG-CoA Synthase (Mitochondrial). * **Detection:** The **Rothera’s Test** detects Acetoacetate and Acetone, but **not** Beta-hydroxybutyrate. * **Energy Yield:** Beta-hydroxybutyrate provides more ATP than Acetoacetate because it starts at a more reduced state (NADH is generated during its conversion back to acetoacetate in peripheral tissues).

Question 104: Which of the following biochemical changes is not indicative of hyperlipidemia type II-A?

A. Total cholesterol increased
B. Triglycerides normal
C. LDL increased
D. HDL increased (Correct Answer)

Explanation: ### Explanation **Fredrickson Classification of Hyperlipoproteinemias** is a high-yield topic for NEET-PG. To answer this question, one must understand the specific lipoprotein elevation associated with **Type II-A Hyperlipidemia** (also known as Familial Hypercholesterolemia). #### Why "HDL increased" is the Correct Answer: In Type II-A hyperlipidemia, the primary defect is a **deficiency or dysfunction of LDL receptors**. This leads to a selective elevation of **Low-Density Lipoprotein (LDL)**. High-Density Lipoprotein (HDL) levels are typically normal or may even be slightly decreased in various hyperlipidemias; an *increase* in HDL is not a diagnostic feature of Type II-A. Therefore, it is the "incorrect" clinical finding among the options. #### Analysis of Incorrect Options: * **A. Total cholesterol increased:** Since LDL is rich in cholesterol, its accumulation significantly raises the total serum cholesterol levels (often >300 mg/dL in heterozygotes). * **B. Triglycerides normal:** This is a pathognomonic feature of Type II-A. Unlike Type II-B (which has elevated VLDL), Type II-A involves only LDL elevation, meaning triglyceride levels remain within the reference range. * **C. LDL increased:** This is the hallmark of Type II-A. The lack of functional LDL receptors prevents the clearance of LDL from the plasma. #### Clinical Pearls for NEET-PG: * **Type II-A (Familial Hypercholesterolemia):** Associated with **Tendon Xanthomas** (especially the Achilles tendon) and Xanthelasma. * **Type II-B:** Elevated LDL + VLDL (increased Cholesterol + Triglycerides). * **Type I & V:** Characterized by milky plasma due to high Chylomicrons. * **Type III (Dysbetalipoproteinemia):** Associated with **Palmar Xanthomas** and elevation of IDL (Broad-beta disease).

Question 105: Which lipoprotein's receptors on blood cells accept cholesterol?

A. HDL
B. LDL (Correct Answer)
C. VLDL
D. Chylomicrons

Explanation: **Explanation:** The correct answer is **LDL (Low-Density Lipoprotein)**. **1. Why LDL is correct:** LDL is the primary carrier of cholesterol in the blood, often referred to as "bad cholesterol." Its main physiological role is to transport cholesterol from the liver to peripheral tissues (including blood cells). This process is mediated by **LDL receptors (Apo B-100/Apo E receptors)** located on the surface of extrahepatic cells. These receptors recognize **Apolipoprotein B-100** on the LDL particle, leading to receptor-mediated endocytosis and the subsequent release of cholesterol into the cell. **2. Why other options are incorrect:** * **HDL (High-Density Lipoprotein):** Known for "Reverse Cholesterol Transport," HDL removes excess cholesterol from peripheral tissues and blood cells and transports it back to the liver. It *donates* cholesterol to the liver rather than cells accepting cholesterol from it. * **VLDL (Very Low-Density Lipoprotein):** Its primary role is the transport of endogenous **triglycerides** from the liver to peripheral tissues. While it contains some cholesterol, it is not the primary vehicle for cellular cholesterol uptake. * **Chylomicrons:** These are responsible for transporting **exogenous (dietary) lipids** (mainly triglycerides) from the intestines to the liver and peripheral tissues. **High-Yield Clinical Pearls for NEET-PG:** * **Apolipoprotein Marker:** LDL is characterized by **Apo B-100**, while Chylomicrons are characterized by **Apo B-48**. * **Friedewald Equation:** LDL Cholesterol = [Total Cholesterol] – [HDL] – [Triglycerides/5]. (Note: This is invalid if TG >400 mg/dL). * **Clinical Correlation:** A deficiency or defect in LDL receptors leads to **Type IIa Familial Hypercholesterolemia**, characterized by xanthomas and early-onset atherosclerosis. * **Rate-limiting enzyme:** HMG-CoA Reductase regulates intracellular cholesterol synthesis; high intracellular cholesterol (delivered by LDL) downregulates this enzyme and the expression of LDL receptors.

Question 106: Which of the following lipids lacks fatty acids?

A. Glycerol
B. Waxes
C. Cholesterol (Correct Answer)
D. Lipoprotein

Explanation: ### Explanation **Correct Answer: C. Cholesterol** **Why Cholesterol is the correct answer:** Lipids are broadly classified into simple, complex, and derived lipids. **Cholesterol** is a **derived lipid** with a steroid nucleus (cyclopentanoperhydrophenanthrene ring). Unlike triglycerides or phospholipids, it does not contain fatty acids in its basic structure. While it can esterify with a fatty acid to form a *cholesterol ester* for storage or transport, the cholesterol molecule itself is a sterol, not an ester of fatty acids. **Analysis of Incorrect Options:** * **A. Glycerol:** While glycerol itself is a trihydroxy alcohol and not a lipid, in the context of lipid metabolism questions, it is often confused with **Glycerides**. However, if the option implies neutral fats (Triacylglycerols), they are esters of glycerol and three **fatty acids**. * **B. Waxes:** These are simple lipids consisting of long-chain **fatty acids** esterified with long-chain monohydric alcohols. * **D. Lipoprotein:** These are complex aggregates (like Chylomicrons, LDL, HDL) that transport lipids in the blood. They contain phospholipids, triglycerides, and cholesterol esters, all of which contain **fatty acids**. **High-Yield Clinical Pearls for NEET-PG:** * **Precursor Role:** Cholesterol is the essential precursor for **Steroid hormones** (cortisol, estrogen, testosterone), **Vitamin D**, and **Bile acids**. * **Membrane Fluidity:** Cholesterol inserts into cell membranes to regulate fluidity; it increases fluidity at low temperatures and decreases it at high temperatures. * **Amphipathic Nature:** Cholesterol is weakly amphipathic due to the hydroxyl (-OH) group at the C3 position. * **Rate-Limiting Enzyme:** HMG-CoA Reductase is the rate-limiting enzyme for cholesterol synthesis (target of Statins).

Question 107: Glucocorticoids and NSAIDs are used to treat inflammatory conditions, but they differ in their use for asthma. Which of the following statements most accurately describes the biochemical mechanism underlying this difference?

A. Steroids inhibit the production of all eicosanoids by blocking phospholipase A2, whereas NSAIDs selectively inhibit the production of prostaglandins and thromboxanes by blocking cyclooxygenase. (Correct Answer)
B. NSAIDs inhibit the production of all eicosanoids by blocking cyclooxygenase, whereas steroids selectively inhibit the production of leukotrienes by blocking lipoxygenase.
C. NSAIDs inhibit the production of leukotrienes and prostaglandins by blocking lipoxygenase and cyclooxygenase, whereas steroids inhibit the production of thromboxanes and leukotrienes by blocking cyclooxygenase and lipoxygenase.
D. Steroids inhibit the production of leukotrienes and prostaglandins by blocking phospholipase A2, whereas NSAIDs inhibit the production of leukotrienes and thromboxanes by blocking lipoxygenase and cyclooxygenase.

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The biochemical difference lies in the level at which these drugs inhibit the **Arachidonic Acid (AA) cascade**. * **Glucocorticoids (Steroids):** Induce the synthesis of **Annexin A1 (Lipocortin)**, which inhibits the enzyme **Phospholipase A2 (PLA2)**. Since PLA2 is responsible for releasing AA from membrane phospholipids, its inhibition shuts down the entire cascade, preventing the formation of **all eicosanoids** (Prostaglandins, Thromboxanes, and Leukotrienes). This broad anti-inflammatory action makes them effective in asthma by reducing bronchoconstrictive leukotrienes. * **NSAIDs (e.g., Aspirin, Ibuprofen):** Specifically inhibit **Cyclooxygenase (COX-1 and COX-2)**. This blocks the production of Prostaglandins and Thromboxanes but **does not** inhibit the Lipoxygenase (LOX) pathway. In fact, by blocking COX, NSAIDs can "shunt" AA toward the LOX pathway, increasing **Leukotriene** production, which can trigger bronchospasm in sensitive asthmatic patients (Aspirin-Exacerbated Respiratory Disease). **2. Analysis of Incorrect Options:** * **Option B:** Incorrectly states NSAIDs block all eicosanoids and steroids selectively block LOX. Steroids are upstream inhibitors; NSAIDs are downstream and selective for COX. * **Option C:** Incorrectly claims NSAIDs block both LOX and COX. Standard NSAIDs do not inhibit LOX. * **Option D:** Incorrectly claims NSAIDs block LOX. While steroids do inhibit both (via PLA2), the description of NSAID action is biochemically inaccurate. **3. NEET-PG High-Yield Pearls:** * **Rate-limiting step of Eicosanoid synthesis:** Release of Arachidonic acid by Phospholipase A2. * **Samter’s Triad:** Asthma, Aspirin sensitivity, and Nasal polyps. * **Zileuton:** A specific 5-LOX inhibitor used in asthma. * **Montelukast/Zafirlukast:** Leukotriene receptor antagonists (CysLT1 receptor). * **Prostaglandin vs. Leukotriene:** PGs are primarily involved in inflammation/fever/pain; LTs (specifically LTC4, LTD4, LTE4) are potent bronchoconstrictors.

Question 108: What is the effect of lipotropic agents on fat metabolism?

A. Increases the rate of fatty acid synthesis in the liver
B. Increases the rate of lipid output from the liver (Correct Answer)
C. Increases the rate of cholesterol synthesis in the liver
D. Decreases the rate of cholesterol synthesis in the liver

Explanation: **Explanation:** **Lipotropic agents** are substances required for the normal mobilization of fat from the liver. The correct answer is **B** because these agents facilitate the synthesis of **Very Low-Density Lipoproteins (VLDL)**. Triglycerides synthesized in the liver cannot be exported as free molecules; they must be packaged into VLDL particles. This process requires phospholipids (like lecithin) and apolipoproteins (Apo B-100). Lipotropic agents (e.g., Choline, Methionine, Betaine, and Inositol) provide the building blocks for these phospholipids. By increasing VLDL assembly, they ensure the efficient export (output) of lipids from the liver to peripheral tissues, thereby preventing the pathological accumulation of fat. **Analysis of Incorrect Options:** * **Option A:** Lipotropic agents do not stimulate fatty acid synthesis (lipogenesis); rather, they manage the disposal of existing lipids. * **Options C & D:** These agents do not primarily target the HMG-CoA reductase pathway or the rate of cholesterol synthesis; their main role is the transport and mobilization of triglycerides. **Clinical Pearls for NEET-PG:** * **Fatty Liver (Steatosis):** A deficiency of lipotropic agents leads to an accumulation of triglycerides in hepatocytes because they cannot be exported, resulting in non-alcoholic fatty liver disease (NAFLD). * **Choline & Methionine:** Choline is a precursor for phosphatidylcholine (lecithin). Methionine is a lipotropic agent because it acts as a methyl donor for the synthesis of choline. * **VLDL:** Remember that VLDL is the primary vehicle for transporting endogenous triglycerides from the liver to the extrahepatic tissues.

Question 109: Which of the following is NOT an essential fatty acid?

A. Arachidonic acid
B. Linoleic acid
C. Palmitic acid (Correct Answer)
D. Linolenic acid

Explanation: **Explanation:** **Essential Fatty Acids (EFAs)** are fatty acids that the human body cannot synthesize de novo because humans lack the enzymes (**desaturases**) capable of introducing double bonds beyond the $\Delta^9$ position. Therefore, they must be obtained through the diet. **Why Palmitic Acid is the Correct Answer:** Palmitic acid (C16:0) is a **saturated fatty acid**. It is the primary product of the Fatty Acid Synthase (FAS) complex in the cytoplasm. Since the body can synthesize it from Acetyl-CoA (derived from excess carbohydrates or proteins), it is considered **non-essential**. **Analysis of Incorrect Options:** * **Linoleic acid (C18:2, $\omega$-6):** A true essential fatty acid. It serves as the precursor for arachidonic acid. * **Linolenic acid (C18:3, $\omega$-3):** A true essential fatty acid. It is vital for cardiovascular health and is a precursor for EPA and DHA. * **Arachidonic acid (C20:4, $\omega$-6):** It is considered **semi-essential**. While it can be synthesized from linoleic acid, it becomes essential if linoleic acid is deficient in the diet. In the context of this question, it is categorized with the essential group. **High-Yield Clinical Pearls for NEET-PG:** 1. **Deficiency Manifestations:** EFA deficiency leads to **Phrynoderma** (follicular hyperkeratosis/toad skin), poor wound healing, and hair loss. 2. **The $\Delta^9$ Rule:** Humans possess $\Delta^4, \Delta^5, \Delta^6,$ and $\Delta^9$ desaturases. We cannot introduce double bonds at $\Delta^{12}$ or $\Delta^{15}$, which is why Linoleic ($\Delta^{9,12}$) and Linolenic ($\Delta^{9,12,15}$) acids are essential. 3. **Energy Yield:** Palmitic acid oxidation yields **106 ATP** (net) via the $\beta$-oxidation pathway.

Question 110: Which organ does not utilize ketone bodies?

A. Liver (Correct Answer)
B. Brain
C. Skeletal muscles
D. Cardiac muscles

Explanation: **Explanation:** The **Liver** is the correct answer because, although it is the primary site of ketone body synthesis (ketogenesis), it lacks the essential enzyme required for their utilization (ketolysis). **1. Why the Liver cannot utilize ketone bodies:** Ketone body utilization requires the conversion of acetoacetate back into acetoacetyl-CoA. This step is catalyzed by the enzyme **Succinyl-CoA:3-ketoacid CoA-transferase (also known as Thiophorase)**. The liver lacks this enzyme. This deficiency is a physiological protective mechanism, ensuring that ketone bodies produced by the liver are exported to extrahepatic tissues for energy during fasting or starvation, rather than being consumed by the liver itself. **2. Why other options are incorrect:** * **Brain:** During prolonged starvation, the brain adapts to use ketone bodies (specifically 3-hydroxybutyrate and acetoacetate) as its primary energy source, meeting up to 75% of its energy requirements to spare glucose. * **Skeletal and Cardiac Muscles:** These tissues possess high levels of Thiophorase. In the early stages of fasting, muscles are the primary consumers of ketone bodies to conserve glucose for the brain. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). * **Ketone bodies include:** Acetone (non-metabolizable, excreted in breath), Acetoacetate, and β-Hydroxybutyrate. * **Key Enzyme for Ketolysis:** Thiophorase (absent in liver). * **Site of Ketogenesis:** Mitochondria of hepatocytes. * **Clinical Sign:** "Fruity odor" of breath in Diabetic Ketoacidosis (DKA) is due to the excretion of acetone.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free